Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11317135 | 0.76 | PTGIR (0.48) | SMN1; SMN2CYP1A2GSK3BRNASEH1CES1 | |
| SCHEMBL6656904 | 0.75 | MMP2 (0.52) | SMN1; SMN2CYP1A2GSK3BRNASEH1KDM4E | |
| SCHEMBL14269110 | 0.71 | MMP2 (0.42) | SMN1; SMN2CYP1A2GSK3BPKMRNASEH1 | |
| SCHEMBL1969272 | 0.71 | ADORA2A (0.64) | SMN1; SMN2GSK3BKDM4EMAPTLMNA | |
| SCHEMBL13150796 | 0.69 | GSK3B (0.61) | SMN1; SMN2GSK3BKDM4EMAPTLMNA | |
| SCHEMBL6372051 | 0.69 | ADORA2A (0.60) | SMN1; SMN2GSK3BKDM4EMAPTLMNA | |
| SCHEMBL9637303 | 0.68 | ALDH1A1 (0.59) | SMN1; SMN2L3MBTL1MAPTCA1CA2 | |
| SCHEMBL17869561 | 0.68 | IMPDH2 (0.44) | CYP1A2GSK3BL3MBTL1PKMRNASEH1 | |
| SCHEMBL7429208 | 0.67 | L3MBTL1 (0.52) | SMN1; SMN2GSK3BL3MBTL1MAPTLMNA | |
| SCHEMBL28171240 | 0.66 | NPSR1 (0.43) | SMN1; SMN2GSK3BL3MBTL1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1264846-C | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | CN | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| CN-1473163-A | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | — | 2004-02-04 | — | — | CN | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | SMN1; SMN2 2364/4885CYP1A2 2676/4885GSK3B 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.